A Textbook of Clinical Pharmacology and Therapeutics

CINACALCET 301

Further reading

Block GA, Martin KJ, de Francisco ALM et al. Cinacalcet for secondary
hyperparathyroidism in patients receiving hemodialysis. New
England Journal of Medicine2004; 350 : 1516–25.

Delmas P. Treatment of postmenopausal osteoporosis. Lancet2002;
359 ; 2018–26.

Jackson RD, LaCroix AZ, Gass M et al. Calcium plus vitamin D sup-
plementation and the risk of fractures. New England Journal of
Medicine2006; 354 : 669–83.

Kleerekoper M, Schein JR. Comparative safety of bone remodeling
agents with a focus on osteoporosis therapies. Journal of Clinical
Pharmacology2001; 41 : 239–50.

Lopez FJ. New approaches to the treatment of osteoporosis. Current
Opinion in Chemical Biology2000; 4 : 383–93.

Marx SJ. Medical progress – Hyperparathyroid and hypoparathyroid

disorders. New England Journal of Medicine2000; 343 : 1863–75.

Meunier PJ, Roux C, Seeman E et al. The effects of strontium ranelate

on the risk of vertebral fracture in women with postmenopausal

osteoporosis. New England Journal of Medicine2004; 350 : 459–68.

Reeve J. Recombinant human parathyroid hormone: osteoporosis is

proving amenable to treatment. British Medical Journal2002; 324 :

435–6.

Reichel H, Koeftler HP, Norman AW. The role of the vitamin D

endocrine system in health and disease. New England Journal of

Medicine1989; 320 : 980–91.

Rosen CJ, Bilezekian JP. Anabolic therapy for osteoporosis. Journal of

Clinical Endocrinology and Metabolism2001; 86 : 957–64.